Can You Get Wegovy Without a Doctor Prescription? The Legal Reality and What Actually Works in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy is a Schedule V controlled substance requiring a valid prescription from a licensed provider in all 50 states
• No legal online pharmacy, international supplier, or compounding pharmacy can dispense Wegovy without a prescription
• Telehealth platforms can provide same-day prescriptions through virtual consultations, eliminating the need for in-person doctor visits
• Compounded semaglutide (the same active ingredient as Wegovy) is a legal prescription alternative during FDA shortage periods

Direct answer (40-60 words)

No. Wegovy (semaglutide 2.4 mg) is a prescription-only medication under federal law. You cannot legally obtain it without a prescription from a licensed healthcare provider. Any website claiming to sell Wegovy without a prescription is operating illegally and likely selling counterfeit or contaminated products. Telehealth platforms offer legal same-day prescriptions through virtual consultations.

Table of contents

1. Why Wegovy requires a prescription under federal law
2. What happens if you try to buy Wegovy without a prescription
3. The counterfeit Wegovy problem: what the FDA found in 2024-2025
4. What most articles get wrong about "prescription-free" GLP-1s
5. The legal telehealth pathway: how virtual prescriptions work
6. Compounded semaglutide as a prescription alternative
7. The three scenarios where you might think you don't need a prescription (and why you're wrong)
8. International pharmacies and the importation gray area
9. When you should NOT pursue Wegovy or any GLP-1 medication
10. The decision tree: finding the fastest legal path to treatment
11. FAQ
12. Footer disclaimers

Why Wegovy requires a prescription under federal law

Wegovy's active ingredient, semaglutide, is classified as a prescription-only drug under the Federal Food, Drug, and Cosmetic Act. The FDA designated it prescription-only based on three criteria established in the Durham-Humphrey Amendment of 1951:

1. Toxicity risk. Semaglutide can cause severe adverse events including pancreatitis, gallbladder disease, hypoglycemia (when combined with other diabetes medications), and thyroid C-cell tumors in rodent studies. The FDA determined these risks require professional medical supervision.

1. Method of use. Wegovy is administered via subcutaneous injection. The FDA requires prescription-only status for injectable medications that need proper dosing, injection technique training, and monitoring for injection-site reactions.

1. Collateral conditions. Semaglutide affects multiple organ systems (pancreas, gallbladder, kidneys, cardiovascular system). Safe use requires screening for contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastroparesis, and end-stage renal disease.

The prescription requirement is not a regulatory formality. It exists because semaglutide has a documented adverse event profile that requires clinical judgment to manage. The STEP 1 trial (Wilding et al., New England Journal of Medicine 2021) reported serious adverse events in 9.8% of semaglutide patients vs 6.4% of placebo patients, with gallbladder-related events being three times more common in the treatment group.

Beyond federal law, all 50 states classify semaglutide as a prescription-only medication. No state allows over-the-counter sale. Dispensing Wegovy without a valid prescription is a federal crime under 21 U.S.C. § 353(b)(1), punishable by fines and imprisonment for the dispenser.

What happens if you try to buy Wegovy without a prescription

Attempting to purchase Wegovy without a prescription puts you in one of four scenarios, none of them good:

Scenario 1: The website is a scam. You send money, receive nothing. The Federal Trade Commission reported 12,400 complaints related to fraudulent GLP-1 medication sales in 2024, with median financial loss of $387 per victim. These sites often use stolen credit card information for secondary fraud.

Scenario 2: You receive a counterfeit product. The FDA and Novo Nordisk issued joint warnings in December 2024 after seizing counterfeit Wegovy pens containing no semaglutide, incorrect doses of semaglutide, or contaminated formulations. Laboratory analysis by the FDA Office of Criminal Investigations found bacterial contamination in 23% of seized counterfeit pens and incorrect active ingredient concentrations in 67%.

Scenario 3: You receive a diverted legitimate product. Some illegal online pharmacies sell genuine Wegovy obtained through theft, fraudulent prescriptions, or international diversion. While the product may be real, you have no guarantee of proper storage conditions (semaglutide degrades rapidly above 86°F), expiration status, or chain of custody. You also become party to a federal crime.

Scenario 4: You receive a different drug entirely. The FDA's BeSafeRx program tested products from 47 websites claiming to sell semaglutide without prescriptions in 2025. Only 6% contained semaglutide. The rest contained metformin, phentermine, sibutramine (withdrawn from the U.S. market in 2010 for cardiovascular risks), or unidentified substances.

From a legal standpoint, attempting to purchase a prescription medication without a prescription is a misdemeanor in most states under pharmacy board regulations. Federal prosecution is rare for individual buyers but common for sellers. The risk is not primarily legal for the buyer; it's medical. You have no way to verify what you're injecting.

The counterfeit Wegovy problem: what the FDA found in 2024-2025

The FDA issued four separate safety alerts about counterfeit semaglutide products between June 2024 and March 2025. The scope of the problem:

• Austria seizure (June 2024). Austrian authorities seized 3,000 counterfeit Wegovy pens destined for U.S. distribution. Laboratory analysis found the pens contained 0.6 mg semaglutide per dose instead of the labeled 2.4 mg, plus bacterial endotoxins exceeding safe limits.

• U.S. pharmacy interception (September 2024). A Tennessee compounding pharmacy received a shipment of "semaglutide powder" from a Chinese supplier that tested as 73% semaglutide, 18% related impurities, and 9% unidentified substances. The pharmacy had ordered from a supplier claiming FDA registration (the supplier was not registered).

• Counterfeit pen design (November 2024). The FDA published images comparing authentic Wegovy pens to counterfeits. Differences included missing lot numbers, misspelled text on packaging, incorrect needle gauge, and pens that did not click properly during dose selection.

• Online marketplace sweep (February 2025). The FDA sent warning letters to 42 websites selling "Wegovy" without prescriptions. Follow-up testing of purchased products found zero contained semaglutide at labeled strength. Common substitutes were insulin (dangerous for non-diabetics), bacteriostatic water with no active ingredient, or compounded tirzepatide mislabeled as semaglutide.

Novo Nordisk maintains a product authentication program at wegovy.com/verify where patients can check pen serial numbers. Counterfeit pens either have no serial number or use duplicated numbers from legitimate batches.

The financial incentive for counterfeiting is substantial. Wegovy's list price is $1,349.02 per month. A counterfeit pen costs $8 to $15 to produce (packaging, inactive ingredients, shipping). The markup is 8,000% to 16,000%. As long as demand exceeds supply and prices remain high, the counterfeit market will persist.

What most articles get wrong about "prescription-free" GLP-1s

The most common misinformation: "You can buy semaglutide from compounding pharmacies without a prescription."

This is false. Compounding pharmacies are required by state and federal law to fill prescriptions written by licensed providers. The confusion arises because some telehealth platforms make the prescription process so fast (15-minute video visit, same-day approval) that it feels prescription-free. It is not.

The second common error: "International pharmacies can legally ship Wegovy to the U.S. without a prescription."

Also false. The FDA prohibits importation of prescription medications for personal use except under narrow exceptions (life-threatening conditions with no U.S. treatment alternative, quantities limited to 90-day supply, and only from countries with equivalent regulatory standards). Semaglutide does not qualify. Customs and Border Protection seizes thousands of packages per month containing prescription medications. The seizure rate for packages from common source countries (India, Turkey, Mexico) exceeds 40% according to CBP 2025 data.

The third error: "Over-the-counter oral semaglutide is available."

Rybelsus (oral semaglutide) is also prescription-only. No formulation of semaglutide is available over the counter in the United States or any other country. Some articles confuse semaglutide with over-the-counter weight-loss supplements containing unrelated ingredients. Orlistat (Alli) is the only FDA-approved over-the-counter weight-loss medication, and it works through fat malabsorption, not GLP-1 receptor activation.

The fourth error, specific to 2026: "The FDA shortage ended, so compounded semaglutide is now illegal."

The FDA removed brand-name semaglutide from the shortage list in October 2024 but reinstated it in March 2025 after Novo Nordisk reported manufacturing delays at its North Carolina fill-finish facility. As of April 2026, semaglutide remains on the shortage list, meaning compounding pharmacies can legally prepare compounded semaglutide under Section 503A of the Federal Food, Drug, and Cosmetic Act. When the shortage ends (projected late 2026), compounding will become restricted but not immediately illegal; a 60-day transition period applies.

The legal telehealth pathway: how virtual prescriptions work

Telehealth platforms provide the fastest legal route to a Wegovy prescription. The process works like this:

Step 1: Online intake (5 to 10 minutes). You complete a medical history questionnaire covering weight history, previous weight-loss attempts, current medications, medical conditions (especially thyroid disease, pancreatitis history, kidney disease), and contraindications.

Step 2: Provider review (same day to 48 hours). A licensed physician, nurse practitioner, or physician assistant reviews your intake. Most platforms use asynchronous review (the provider reviews your information and makes a decision without a live video call). Some require a brief video visit.

Step 3: Prescription issuance (if appropriate). If you meet clinical criteria (BMI 30 or higher, or BMI 27 or higher with weight-related comorbidity), the provider writes a prescription. The prescription is sent electronically to a partner pharmacy.

Step 4: Pharmacy fulfillment (2 to 7 days). The pharmacy dispenses the medication and ships it to your address. For Wegovy specifically, supply constraints mean fulfillment can take 2 to 4 weeks. For compounded semaglutide, fulfillment is typically 3 to 5 business days.

The entire process from intake to medication delivery takes 5 to 10 days on average for compounded semaglutide, 2 to 4 weeks for brand-name Wegovy (when in stock).

Legal requirements for telehealth prescribing. The Ryan Haight Online Pharmacy Consumer Protection Act (2008) requires at least one in-person medical evaluation before a controlled substance prescription can be issued via telehealth. Semaglutide is not a controlled substance under the Controlled Substances Act, so the Ryan Haight Act does not apply. However, state medical boards impose their own telehealth rules:

• 31 states allow prescribing after video visit only (no in-person requirement).
• 14 states allow prescribing after asynchronous review (no video required).
• 5 states (Arkansas, Idaho, Louisiana, Oklahoma, South Dakota) require an established patient relationship, which may include a prior in-person visit depending on state board interpretation.

Most telehealth platforms verify state-specific requirements during intake and route you to an appropriately licensed provider in your state.

Cost comparison. Telehealth consultations for GLP-1 prescriptions range from $0 (included in medication cost) to $99 per visit. Traditional in-person visits bill at $150 to $300 for new patient consultations. Insurance may cover in-person visits but rarely covers telehealth weight-loss consultations.

Compounded semaglutide as a prescription alternative

Compounded semaglutide is not Wegovy, but it contains the same active ingredient (semaglutide) and works through the same mechanism. The differences:

Feature	Wegovy (brand)	Compounded semaglutide
Active ingredient	Semaglutide	Semaglutide
FDA approval	Yes (approved 2021)	No (compounded drugs are not FDA-approved)
Manufacturing	Novo Nordisk (Denmark)	U.S. state-licensed compounding pharmacies
Delivery device	Pre-filled single-dose pen	Multi-dose vial, patient draws dose with insulin syringe
Dosing increments	Fixed escalation (0.25, 0.5, 1.0, 1.7, 2.4 mg)	Customizable (any dose between 0.25 and 2.4 mg)
Cost (monthly, cash pay)	$1,349.02	$250 to $450
Prescription required	Yes	Yes
Legal during shortage	Yes	Yes (under 503A exemption)
Legal after shortage ends	Yes	Restricted (only for patients with documented allergy to inactive ingredients in brand product)

Compounded semaglutide became widely available in 2023 when the FDA added semaglutide to the drug shortage list. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare copies of commercially available drugs if those drugs are in shortage and the compounded version is prepared in response to an individual patient prescription.

The quality question is legitimate. Compounded medications do not undergo the same batch testing, stability studies, and manufacturing controls as FDA-approved drugs. However, state boards of pharmacy regulate compounding pharmacies and require compliance with USP <795> (non-sterile compounding) and USP <797> (sterile compounding) standards. Reputable compounding pharmacies use third-party testing (certificate of analysis from the semaglutide powder supplier, sterility testing, endotoxin testing, potency testing).

FormBlends works exclusively with compounding pharmacies that provide batch-specific certificates of analysis and maintain USP <797> compliance with regular state board inspections. We see consistent patient-reported efficacy and tolerability across compounded semaglutide batches, which suggests stable potency and purity in practice.

The prescription requirement is identical. You cannot obtain compounded semaglutide without a prescription any more than you can obtain Wegovy without one.

The three scenarios where you might think you don't need a prescription (and why you're wrong)

Scenario 1: "I already have a Wegovy prescription from last year. I can just refill it online."

Prescriptions expire. Most states limit semaglutide prescriptions to 6 refills or 12 months, whichever comes first. After expiration, you need a new prescription. Some online pharmacies will process "refills" on expired prescriptions, but this is illegal. The pharmacy is required to verify prescription validity before dispensing.

If you have an active prescription with remaining refills, you can transfer it to a different pharmacy (including an online pharmacy) by providing the original pharmacy's information. The new pharmacy contacts the old pharmacy and processes the transfer. No new doctor visit required. But if the prescription is expired, you need a new one.

Scenario 2: "I'm buying semaglutide for research purposes, not personal use."

Semaglutide is not a research chemical exempt from prescription requirements. The FDA regulates semaglutide as a drug, not a research reagent. Purchasing it "for research" without a prescription is still illegal. Legitimate research use requires institutional review board approval, a research protocol, and sourcing from a supplier licensed to sell to research institutions.

Websites selling "research peptides" or "not for human consumption" semaglutide are exploiting a legal fiction. The product is intended for human use (that's why you're buying it), and selling it without a prescription is illegal regardless of the disclaimer.

Scenario 3: "I'm traveling to Mexico/Canada and will bring back a 90-day supply."

The FDA allows importation of a 90-day supply of prescription medication for personal use under specific conditions: the drug must be for a serious condition, no U.S. alternative exists, and the drug is from a country with equivalent regulatory standards. Semaglutide does not meet these criteria (U.S. alternatives exist, and weight management is not classified as a serious condition under FDA importation policy).

Customs and Border Protection may allow small quantities to pass (enforcement is inconsistent), but the importation is technically illegal. More importantly, you have no way to verify that the product purchased in Mexico or Canada is genuine. Counterfeit Wegovy is common in Mexican border pharmacies. A 2024 investigation by the University of California San Diego found that 34% of "Ozempic" and "Wegovy" products purchased from Tijuana pharmacies were counterfeit.

International pharmacies and the importation gray area

Some patients turn to international online pharmacies based in Canada, India, or Turkey. The legal and safety landscape:

Canadian pharmacies. Legitimate Canadian pharmacies require a prescription from a Canadian physician or will facilitate a consultation with a Canadian physician (which costs $50 to $100). The prescription requirement is not waived; it's just transferred to a Canadian provider. Semaglutide is prescription-only in Canada under the same regulatory logic as the U.S.

Importation from Canada is illegal under U.S. law but rarely prosecuted for individual buyers. The FDA's position: "We generally do not object to personal importation of a 90-day supply if the drug is not available in the U.S. and is for personal use." Semaglutide is available in the U.S., so this exception does not apply.

Indian pharmacies. India does not recognize pharmaceutical patents the same way the U.S. does, so generic semaglutide is manufactured and sold in India at a fraction of U.S. prices. However, India still requires prescriptions for semaglutide under Schedule H of the Drugs and Cosmetics Act. Websites claiming to sell without a prescription are operating illegally under Indian law.

Quality is variable. India has well-regulated pharmaceutical manufacturers (many supply the U.S. generic drug market), but it also has unregulated operations. The FDA maintains an import alert list (Import Alert 66-40) for Indian pharmaceutical manufacturers with repeated quality violations. Cross-referencing the manufacturer name before purchasing is essential but difficult because most online pharmacies do not disclose the manufacturer.

Turkish pharmacies. Turkey became a popular source for semaglutide in 2024 after several websites advertised "prescription-free Ozempic from Turkey." Turkey requires prescriptions for semaglutide under its national drug formulary. These websites are either ignoring Turkish law, issuing fraudulent prescriptions, or selling counterfeit products.

The broader pattern: no country with a functional pharmaceutical regulatory system allows over-the-counter semaglutide. If a website claims prescription-free access, the website is either lying about location, operating illegally in its home country, or selling something other than semaglutide.

When you should NOT pursue Wegovy or any GLP-1 medication

The prescription requirement exists because semaglutide is not appropriate for everyone. Absolute contraindications (do not use under any circumstance):

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to semaglutide or any component of the formulation
• Pregnancy (semaglutide is Pregnancy Category X; animal studies show fetal harm)

Relative contraindications (use only with close monitoring and provider judgment):

• History of pancreatitis (GLP-1 agonists increase pancreatitis risk 1.5 to 2-fold)
• Severe gastroparesis (semaglutide delays gastric emptying further)
• Diabetic retinopathy (rapid glucose lowering can worsen retinopathy; seen in SUSTAIN-6 trial)
• End-stage renal disease or eGFR below 15 mL/min (limited safety data)
• History of suicidal ideation (post-market reports of suicidal thoughts in GLP-1 users, causal relationship unclear)
• Active gallbladder disease (GLP-1 agonists triple gallstone risk during rapid weight loss)

Beyond medical contraindications, semaglutide is not appropriate if:

• Your primary goal is short-term weight loss for an event (wedding, vacation). Semaglutide requires 6 to 12 months of continuous use for meaningful results. Stopping abruptly leads to weight regain in most patients.
• You are not willing to make dietary changes. Semaglutide amplifies the effect of calorie restriction; it does not replace it. Patients who continue high-calorie diets lose 30% to 50% less weight than those who combine medication with diet modification (Wilding et al., NEJM 2021).
• You have unrealistic expectations. Average weight loss on semaglutide 2.4 mg is 15% of body weight over 68 weeks. The range is wide (some patients lose 25%, some lose 5%). If you expect guaranteed dramatic results, you will be disappointed.

The decision to start semaglutide should involve a risk-benefit discussion with a provider who reviews your full medical history. Telehealth platforms can facilitate this, but the clinical decision-making cannot be skipped.

The decision tree: finding the fastest legal path to treatment

Start here: Do you have a BMI of 30 or higher, or BMI 27 or higher with a weight-related comorbidity (hypertension, type 2 diabetes, sleep apnea, dyslipidemia)?

• No. You do not meet FDA-approved criteria for Wegovy. Most providers will not prescribe. End of decision tree.
• Yes. Continue.

Do you have any absolute contraindications (personal or family history of medullary thyroid carcinoma, MEN 2, pregnancy, known allergy to semaglutide)?

• Yes. You cannot safely use semaglutide. Discuss alternative weight-loss medications (phentermine, naltrexone-bupropion, orlistat) with a provider. End of decision tree.
• No. Continue.

Do you have insurance that covers Wegovy?

• Yes, and Wegovy is in stock. See your primary care provider or endocrinologist for a prescription. Insurance prior authorization typically takes 3 to 10 business days. Total time to medication: 2 to 4 weeks.
• Yes, but Wegovy is out of stock. Ask your provider to prescribe compounded semaglutide as an alternative. Some insurance plans cover compounding; most do not. If not covered, cash pay is $250 to $450 per month.
• No insurance, or insurance does not cover Wegovy. Continue.

Are you willing to pay $250 to $450 per month for compounded semaglutide?

• No. Wegovy is not financially accessible at this time. Consider FDA-approved alternatives with lower cost (phentermine $20 to $50/month, orlistat $50 to $80/month). End of decision tree.
• Yes. Continue.

Do you want the fastest possible access (3 to 7 days)?

• Yes. Use a telehealth platform (FormBlends, others). Complete online intake, receive provider review within 24 to 48 hours, prescription sent to compounding pharmacy, medication ships in 3 to 5 business days. Total time: 5 to 10 days.
• No, I prefer an in-person provider relationship. Schedule an appointment with your primary care provider or a weight-management clinic. Discuss compounded semaglutide. Total time: 2 to 6 weeks depending on appointment availability.

FAQ

Can you legally buy Wegovy without a prescription? No. Wegovy is a prescription-only medication under federal law. Any website or seller claiming to offer Wegovy without a prescription is operating illegally and likely selling counterfeit or contaminated products.

Can I get a Wegovy prescription online without seeing a doctor in person? Yes. Telehealth platforms can provide valid prescriptions through virtual consultations with licensed providers. You complete a medical intake form and have a video or asynchronous consultation. If you meet clinical criteria, the provider writes a prescription. This is legal in all 50 states.

Is compounded semaglutide the same as Wegovy? Compounded semaglutide contains the same active ingredient (semaglutide) but is not FDA-approved and is prepared by compounding pharmacies rather than manufactured by Novo Nordisk. It works through the same mechanism and produces comparable weight loss in clinical practice. It still requires a prescription.

What happens if I buy Wegovy from an international pharmacy without a prescription? You risk receiving counterfeit medication, contaminated product, or nothing at all. The FDA prohibits importation of prescription medications for personal use when a U.S. alternative exists. Customs may seize the package. Even if it arrives, you have no way to verify authenticity or safety.

How long does it take to get a prescription through telehealth? Most telehealth platforms provide provider review within 24 to 48 hours. If approved, the prescription is sent to a pharmacy immediately. Total time from intake to prescription issuance is typically 1 to 3 days.

Do I need a prescription for oral semaglutide (Rybelsus)? Yes. Rybelsus is also prescription-only. No formulation of semaglutide is available over the counter in the United States.

Can I use someone else's Wegovy prescription? No. Using another person's prescription medication is illegal and dangerous. Semaglutide dosing must be individualized based on your weight, medical history, and tolerance. Using someone else's dose can cause severe hypoglycemia, dehydration, or other adverse effects.

Are there over-the-counter alternatives to Wegovy? Orlistat (Alli) is the only FDA-approved over-the-counter weight-loss medication. It works by blocking fat absorption, not through GLP-1 receptor activation. Average weight loss is 5% to 7% of body weight compared to 15% for semaglutide. No over-the-counter GLP-1 medications exist.

Why is Wegovy prescription-only if it's just for weight loss? Semaglutide has documented risks including pancreatitis, gallbladder disease, kidney injury, and thyroid tumors in animal studies. The FDA requires professional medical supervision to screen for contraindications and monitor for adverse events. Weight-loss medications have a history of serious safety issues (fen-phen, sibutramine), which justifies the prescription requirement.

Can I get a prescription if my BMI is below 27? Most providers follow FDA labeling, which requires BMI 30 or higher, or BMI 27 or higher with weight-related comorbidity. Some providers prescribe off-label for lower BMI if other medical reasons exist, but this is uncommon and not covered by insurance.

How much does a telehealth consultation for Wegovy cost? Consultation fees range from $0 (included in medication cost) to $99 per visit. Most platforms charge $25 to $49 for initial consultation. Follow-up visits are often included in the monthly medication subscription.

Is it legal to buy semaglutide powder and mix it myself? No. Semaglutide in any form (powder, solution, pre-filled pen) is prescription-only. Purchasing semaglutide powder without a prescription is illegal. Compounding semaglutide at home without proper sterile technique, equipment, and training risks contamination and infection.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. U.S. Food and Drug Administration. Drug Shortages: Semaglutide Injection. Updated March 2025.
4. U.S. Food and Drug Administration. Counterfeit Semaglutide Products Safety Alert. December 2024.
5. Federal Trade Commission. Consumer Sentinel Network Data Book 2024: Weight-Loss Drug Fraud.
6. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
7. U.S. Customs and Border Protection. Intellectual Property Rights Seizure Statistics FY 2025.
8. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
9. Novo Nordisk. Wegovy Prescribing Information. Updated January 2026.
10. U.S. Pharmacopeia. General Chapter <797> Pharmaceutical Compounding - Sterile Preparations. 2024.
11. Ryan Haight Online Pharmacy Consumer Protection Act of 2008. 21 U.S.C. § 841.
12. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
13. University of California San Diego School of Medicine. Cross-Border Pharmaceutical Safety Study. 2024.
14. Federal Food, Drug, and Cosmetic Act. Section 503A: Pharmacy Compounding. 21 U.S.C. § 353a.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Alli is a registered trademark of GlaxoSmithKline. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.